IBRANCE®
(EYE-brans)
(Palbociclib)

Chemotherapy 

IBRANCE®
(EYE-brans)
(Palbociclib)

Chemotherapy

What is IBRANCE (Palbociclib)?

IBRANCE is a prescription medicine used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) in combination with:

It is not known if IBRANCE is safe and effective in children.

What is the most important information I should know about IBRANCE?

IBRANCE can cause serious side effects. These serious side effects include:

How should I take IBRANCE?

Nucleic Acid Diagnostic kit

Important Safety Information

Ask your healthcare provider if you do not know.

What should I tell my healthcare provider before taking IBRANCE?

Before you take IBRANCE, tell your healthcare provider if you:

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. IBRANCE and other medicines may affect each other causing side effects.

Available 24/7
Experiencing
symotoms that
concern you

General information about IBRANCE

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IBRANCE for a condition for which it was not prescribed. Do not give IBRANCE to other people, even if they have the same symptoms you have. It may harm them.

What are the ingredients in IBRANCE?

Active ingredient: Palbociclib

Inactive ingredient: Microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and hard gelatin capsule shells. 

Light orange, light orange/caramel and caramel opaque capsule shells contain: gelatin, red iron oxide, yellow iron oxide, and titanium dioxide. 

Have questions about chemotherapy?

Contact for Second Opinion or Free Counselling

Available 24/7
Experiencing
symotoms that
concern you
Have questions
about cancer?
Just ask Alexa. Find voice-activated answers to 800+ questions on 40+ cancer types.